Anlotinib Hydrochloride for Soft Tissue Sarcoma Patients.
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the
angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR),
Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and
tumor cell proliferation related kinase c-Kit kinase. Anlotinib is an efficient second line
therapeutic agent in treatment for metastatic soft tissue sarcoma which has been approved in
clinical trials (ALTER-0203). Therefore, this study evaluates the safety and efficacy of
anlotinib as maintenance treatment of disease control in advanced soft tissue sarcoma.